Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by XOMA Corporation

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Royalty to Present at Upcoming Investor Conferences in September
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Corporation Announces Closing of Tender Offer
From XOMA Corporation
Via GlobeNewswire
Tickers KNTE XOMA XOMAO XOMAP
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
From XOMA Corporation
Via GlobeNewswire
Tickers KNTE XOMA XOMAO XOMAP
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA to Present at Upcoming Investor Conferences in March
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
From XOMA Corporation
Via GlobeNewswire
Tickers KNTE XOMA XOMAO XOMAP
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Announces Stock Repurchase Program of up to $50 Million
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
From XOMA Corporation
Via GlobeNewswire
Tickers OWL XOMA XOMAO XOMAP
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Added to the Russell 2000® and Russell 3000® Indexes
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
From XOMA Corporation
Via GlobeNewswire
Tickers XOMA XOMAO XOMAP
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.